Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 01 2021
Historique:
received: 09 07 2020
accepted: 19 08 2020
pubmed: 28 8 2020
medline: 22 6 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

This report describes the persistence of late substantial treatment-related patient-reported symptoms (LAPERS) in the multi-institutional EMBRACE study on magnetic resonance image guided adaptive brachytherapy in locally advanced cervical cancer (LACC). Patient-reported symptoms (European Organization for Research and Treatment of Cancer [EORTC]-C30/CX24) and physician-assessed morbidity (Common Terminology Criteria for Adverse Events [CTCAE], version 3.0) were assessed at baseline and regular timepoints during follow-up. Patients with sufficient EORTC follow-up (baseline and ≥3 late follow-up visits) were analyzed. LAPERS events were defined as the presence of substantial EORTC symptoms (quite a bit/very much) for at least half of the assessments (persistence) and progression beyond baseline condition (treatment-related). For each EORTC symptom, the ratio between LAPERS rates and crude incidence rates of substantial symptoms was calculated to represent the proportion of symptomatic patients with persisting symptoms. For 9 symptoms with a corresponding EORTC/CTCAE assessment, the overlap of LAPERS and severe morbidity events (grades 3-5) was evaluated. Of 1047 patients with EORTC available, 741 had sufficient follow-up for the LAPERS analyses. The median follow-up was 59 months (interquartile range, 42-70 months). Across all symptoms, the proportion of patients with LAPERS events (LAPERS rates) was in median 4.6% (range, 0.0% vaginal bleeding to 20.4% tiredness). Urinary frequency, neuropathy, fatigue, insomnia, and menopausal symptoms revealed LAPERS rates of >10%. Vomiting, blood in stool, urinary pain/burning, and abnormal vaginal bleeding displayed LAPERS rates of <1%. A median of 19% of symptomatic patients (interquartile range, 8.0%-28.5%) showed persistent long-term symptoms (LAPERS events). In symptoms with a corresponding EORTC/CTCAE assessment, 12% of LAPERS events were accompanied by a severe CTCAE event. Within this large cohort of survivors of LACC, a subgroup of patients with persistent symptoms (LAPERS events) was identified. For symptoms with a corresponding EORTC/CTCAE assessment, the vast majority of LAPERS events occurred in patients without corresponding severe physician-assessed morbidity. These findings emphasize the importance of distinguishing between transient and persisting symptoms in the aftercare of LACC survivors.

Identifiants

pubmed: 32853710
pii: S0360-3016(20)34139-0
doi: 10.1016/j.ijrobp.2020.08.044
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

161-173

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Anders S Vittrup (AS)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: anders.vittrup@oncology.au.dk.

Kari Tanderup (K)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Søren M Bentzen (SM)

Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland.

Nina B K Jensen (NBK)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Sofia Spampinato (S)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Lars U Fokdal (LU)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Jacob C Lindegaard (JC)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Alina Sturdza (A)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna/General Hospital of Vienna, Vienna, Austria.

Maximilian Schmid (M)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna/General Hospital of Vienna, Vienna, Austria.

Barbara Segedin (B)

Department of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia.

Ina M Jürgenliemk-Schulz (IM)

Department of Radiation Oncology, University Medical Centre, Utrecht, The Netherlands.

Kjersti Bruheim (K)

Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Umesh Mahantshetty (U)

Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India.

Christine Haie-Meder (C)

Department of Radiotherapy, Gustave-Roussy, Villejuif, France.

Bhavana Rai (B)

Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Rachel Cooper (R)

Leeds Cancer Centre, St James's University Hospital, Leeds, United Kingdom.

Elzbieta van der Steen-Banasik (E)

Radiotherapiegroep, Arnhem, The Netherlands.

Marit Sundset (M)

Clinic of Oncology and Women's Clinic, St. Olavs Hospital, Trondheim, Norway.

Fleur Huang (F)

Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, Alberta Canada.

Remi A Nout (RA)

Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.

Elena Villafranca (E)

Department of Radiation Oncology, Hospital of Navarra, Pamplona, Spain.

Erik Van Limbergen (E)

Department of Radiation Oncology, Universitair Ziekenhuis Leuven, Leuven, Belgium.

Bradley R Pieters (BR)

Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

Li Tee Tan (LT)

Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom.

Ludy C H W Lutgens (LCHW)

Maastricht Radiation Oncology (MAASTRO) Clinic, Maastricht, The Netherlands.

Peter Hoskin (P)

Cancer Centre, Mount Vernon Hospital, London, United Kingdom.

Richard Pötter (R)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna/General Hospital of Vienna, Vienna, Austria.

Kathrin Kirchheiner (K)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna/General Hospital of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH